The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.
Natalie Faye Sinclair
No relevant relationships to disclose
Maysa M. Abu-Khalaf
Consultant or Advisory Role - Celgene
Honoraria - Abraxis BioScience
Research Funding - Abraxis BioScience; Roche/Genentech
Tina Rizack
No relevant relationships to disclose
Kayla Rosati
No relevant relationships to disclose
Gina Chung
No relevant relationships to disclose
Robert Duffy Legare
No relevant relationships to disclose
Michael DiGiovanna
No relevant relationships to disclose
Mary Anne Fenton
No relevant relationships to disclose
Veerle Bossuyt
Honoraria - Roche
Other Remuneration - Roche
Rochelle Strenger
No relevant relationships to disclose
Bachir Joseph Sakr
No relevant relationships to disclose
Donald R. Lannin
No relevant relationships to disclose
Jennifer S. Gass
No relevant relationships to disclose
Lyndsay Harris
Consultant or Advisory Role - Celgene; Roche/Genentech
Research Funding - Celgene; Roche/Genentech
William M. Sikov
Consultant or Advisory Role - Celgene
Research Funding - Abraxis BioScience